In this episode, listeners will better understand what innovative content is in the context of Medical Information while setting expectations of HCPs in accessing innovative content.
Advisory boards bring together a selection of key opinion leaders to discuss a topic important to a life sciences company. Here is how to use engagement technologies to generate actionable insights from your next ad board.
This Webinar series explores the fundamental concept of big data in Medical Affairs, from which sources can we retrieve this, what are the broader considerations when utilizing data in health and what impact this can have on our organizations, physicians, and patients, now and in the future.
In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Robin Winter-Sperry and Robert Kersting, PharmD, Global Head, Scientific Alliances, Novartis, about the need for multi-stakeholder partnerships.
In this interview recorded at the MAPS 2023 Annual Meeting in Nashville, MAPS speaks with Jim Wilkinson, PhD, Vice President, Global & US Medical Affairs, Amgen, about how to develop Medical Affairs talent into tomorrow’s leaders.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.
This Standard and Guidance, a collaboration between MAPS, PhactMI, MILE, is intended to inform learners about the Medical Information (MI) function, strategic direction, and operations across multiple geographies.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.
This presentation, part 3 of 3, provides insights into the types of communications that the FDA has indicated are or are not permissible, and the uncertainties that still remain.